Omni Health, Inc., (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today that it has received $1,000,000 in financing through private investors exempt from registration and restricted under Rule 144 of the Securities Exchange Act of 1933. The financing will allow OMHE to accelerate planned growth into key health technology fields.

"The investors confidence in Omni Health, its vision, and its management team was the catalyst needed for the implementation of OMHE's long anticipated and well thought out strategic growth and expansion plans," says Omni Health CEO, Andrey Soloviev. He went on to say, "This financing is a win for our shareholders, as it will help move our innovation and growth moving forward, and to further our efforts in long-pursued cannabis biotechnology product acquisitions, research, and development. In the upcoming weeks, Omni Health will lay out for its shareholders its ambitious and strategic goals that will lead to greater revenue resources to complement the $6 million in existing annual revenue, making this an attractive investment for our reputable, principled investors."

The Company expects to use the proceeds from the transaction primarily to advance its pipeline into several healthcare related fields with diverse and global growth potential, including specialty pharmaceuticals, anti-aging brands and therapeutic cannabis products.

For more information on Omni Health, visit the company's new website at www.OmniHealth.md